ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Innovassynth filed the ACER Monitoring Agency Report for the quarter ended 30 September 2026 on Rights Issue proceeds. The report finds no deviation from the stated objects.
Q2FY27 revenue Rs47.6 Cr (+175% YoY, -15% QoQ), EBITDA margin 4%, PAT Rs1.5 Cr. H1 revenue Rs103.5 Cr, PAT Rs8.2 Cr. Order book Rs137 Cr.
Innovassynth's board approved re-appointment of Dr. Hardik Joshipura as MD & CEO for three years from February 12, 2027, subject to shareholder approval. The filing is a Regulation 30 senior-appointment disclosure.
Innovassynth Technologies (India) Ltd reported revenue from operations of ₹47.5 Cr (+174.6% YoY) and net profit of ₹1.5 Cr for Q2 FY27.
Innovassynth Technologies will hold a board meeting on 2 November 2026 to consider unaudited half-year results. The filing is a prior intimation with proposed agenda only.
Innovassynth Technologies (India) Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with regulatory filings.
Innovassynth Technologies held its 18th Annual General Meeting on September 30, 2026. Members transacted business through remote e-voting and OAVM in accordance with standard procedures.
Innovassynth Technologies (India) Limited filed its Annual Report for FY 2025-26, including audited financial statements and notice convening the 18th Annual General Meeting.
Innovassynth Technologies will hold its 18th Annual General Meeting on September 30, 2026, via video conferencing. The remote e-voting cut-off date is September 23, 2026.
Innovassynth Technologies submitted the Monitoring Agency Report for the quarter ended June 30, 2026, confirming proceeds from the Rights Issue were utilized per the Letter of Offer.
Innovassynth reported sharp Q1FY27 recovery with Revenue of ₹55.99 Cr and 27% EBITDA margin. Strategy focuses on CRDMO expansion in Life Sciences and Specialty Chemicals for US/EU markets.
Innovassynth Technologies (India) Ltd reported revenue from operations of ₹56 Cr (+355.3% YoY) and net profit of ₹6.7 Cr for Q1 FY27.
Innovassynth Technologies scheduled a board meeting for August 12, 2026, to approve unaudited standalone financial results for the quarter ended June 30, 2026.
Innovassynth Technologies (India) Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI regulations.
Innovassynth reported Q4FY26 revenue of ₹50.8cr and PAT of ₹12cr. The company is transitioning towards a CDMO-focused model with significant capacity expansion in Life Sciences.
Innovassynth Technologies filed its Annual Secretarial Compliance Report for FY2026. The report notes a minor procedural non-compliance regarding the timeline for prior board meeting intimations.
Innovassynth Technologies paid an ₹0.01 Crore fine to BSE for delayed board meeting intimation. The board confirmed corrective actions to prevent future compliance lapses.
Innovassynth Technologies (India) Ltd reported revenue from operations of ₹50.8 Cr (+5.0% YoY) and net profit of ₹12 Cr (+3.4% YoY) for Q4 FY26.
Innovassynth Technologies approved its audited financial results for the year ended March 31, 2026. The board also approved reports for the 2025-26 fiscal year.
Innovassynth Technologies (India) Ltd scheduled a board meeting for May 29, 2026. Directors will review and approve audited financial results for fiscal 2026.
Innovassynth Technologies (India) Ltd allotted 1,40,69,636 equity shares to promoter group members via a rights issue. The group's total holding increased from 73.70% to 75.04%.
Innovassynth Technologies allotted 1,74,11,380 equity shares via a ₹69.65 Crore rights issue. The issue was oversubscribed by 155.29%, strengthening the company's capital base.
Innovassynth Technologies scheduled a May 19, 2026, committee meeting to approve rights issue share allotments. This follows the scheduled May 18 issue closure.